F-1/A: NewGenIvf Group Navigates Financial Headwinds with Strategic Acquisitions and Capital Injections Amidst Nasdaq Compliance Efforts

NewGenIvf Group Limited reported a net loss in 2024 despite revenue growth, while actively securing significant capital and acquiring key technology to fuel its expansion in the Asia-Pacific assisted reproductive services market.

Summary

• NewGenIvf Group Limited, an assisted reproductive services (ARS) provider in Asia-Pacific, reported a net loss of $474,101 for the year ended December 31, 2024, compared to a net income of $108,418 in 2023.
• Revenue increased by approximately 5.8% from $5,136,153 in 2023 to $5,433,375 in 2024, primarily driven by a 35.1% increase in IVF treatment services revenue.
• The company experienced a significant increase in operating expenses, rising 82.2% from $1,639,543 in 2023 to $2,987,389 in 2024, due to professional fees for business combination and financing, MicroSort technology license fees, and increased staff and director salaries for business expansion.
• NewGenIvf successfully regained compliance with Nasdaq listing requirements, including the minimum bid price rule and market value of listed securities, after implementing a 1-for-20 reverse stock split on February 11, 2025, and transferring its listing to the Nasdaq Capital Market on February 28, 2025.
• The company completed the acquisition of MicroSort technology from Genetics & IVF Institute, Inc. on February 28, 2025, for $750,000 cash and 12,500 Class A Ordinary Shares, gaining exclusive ownership of this pre-conception gender selection technology.
• NewGenIvf secured an equity line of credit facility of up to $100 million (expandable to $500 million) from White Lion Capital, LLC, with approximately $7.1 million already drawn as of the filing date.
• The company also engaged in debt financing with JAK Opportunities VI LLC, issuing senior convertible notes totaling $3.15 million, of which $2.65 million has been converted into 35,105 Class A Ordinary Shares (post-split) as of December 31, 2024, and an additional $2 million note issued in April 2025.
• Surrogacy and ancillary caring services revenue decreased by 100% to Nil in 2024 from $1,114,457 in 2023, attributed to a reorganization of Kyrgyzstan business operations, including the sale of First Fertility Bishkek LLC and acquisition of Bi Clinic Limited Liability Corporation.
• As of December 31, 2024, the company had an accumulated deficit of $985,994 and a total shareholders' deficit of $1,481,757, raising substantial doubt about its ability to continue as a going concern.
• A 1-for-10 reverse stock split was approved on April 15, 2025, and became effective on May 5, 2025, to maintain Nasdaq compliance.

Sentiment

Score: 4

Explanation: The company faces significant financial challenges, including a net loss, accumulated deficit, and negative shareholder equity, raising going concern doubts. While strategic acquisitions and capital raises are positive, the current financial state and past failures in M&A attempts indicate high risk and uncertainty.

Positives

• Revenue increased by 5.8% year-over-year, from $5,136,153 in 2023 to $5,433,375 in 2024, driven by a 35.1% growth in IVF treatment services.
• Successfully regained compliance with Nasdaq's minimum bid price rule and other listing requirements, including transferring to the Nasdaq Capital Market, which mitigates immediate delisting risks.
• Acquired exclusive ownership of MicroSort technology, a pre-conception gender selection technology, which is expected to enhance service offerings and competitive advantage.
• Secured a significant equity line of credit facility of up to $100 million (expandable to $500 million) from White Lion Capital, providing substantial potential capital for future operations and growth.
• Ongoing debt financing arrangements with JAK Opportunities VI LLC, with convertible notes providing additional capital and flexibility.
• Strategic expansion plans include investing in laboratory and facility upgrades, increasing brand awareness, and exploring acquisitions and partnerships in the Asia-Pacific ARS market.
• The company's average cost per IVF cycle is around $7,000 (excluding medication), which is relatively low compared to the U.S. market, making its services cost-effective for clients.

Negatives

• The company reported a net loss of $474,101 in 2024, a significant decline from a net income of $108,418 in 2023.
• Operating expenses increased substantially by 82.2% in 2024, impacting profitability.
• The company has an accumulated deficit of $985,994 and a total shareholders' deficit of $1,481,757 as of December 31, 2024, raising substantial doubt about its ability to continue as a going concern.
• Surrogacy and ancillary caring services revenue dropped to Nil in 2024 due to reorganization in Kyrgyzstan, eliminating a previous 21.7% revenue stream.
• Two proposed reverse merger transactions (with COVIRIX and EWIHL) were terminated, indicating challenges in executing strategic M&A.
• The company has a limited operating history with its current platform of solutions, making future financial performance difficult to predict.
• The company has historically failed to file timely financial statements with the SEC, which could lead to further enforcement actions or delisting.

Risks

• The company may not be able to continue operating as a going concern due to its accumulated deficit and negative shareholders' equity, and there is no assurance that required financings will be available on acceptable terms.
• The fertility market is highly competitive, and NewGenIvf may struggle to compete effectively against more established players with greater resources, potentially leading to decreased client base and market share.
• NewGenIvf's limited operating history with its current solutions makes it difficult to predict future prospects, financial performance, and results of operations.
• Failure to attract new clients or maintain existing client demographics could adversely affect business, financial condition, and results of operations.
• The company's marketing efforts are heavily reliant on positive client references, and dissatisfaction could harm its brand and reputation.
• NewGenIvf may experience net losses and may not sustain profitability in the future, as costs are expected to increase with expansion efforts.
• Future revenue growth may not match historical rates or may decline due to various factors including slowing demand, increased competition, or economic downturns.
• The company's interim and annual results may fluctuate significantly, making period-to-period comparisons unreliable.
• Inaccurate estimates of target market size could impact future growth rates.
• NewGenIvf may not be able to successfully manage its growth, leading to reduced client satisfaction and lower revenue growth.
• Failure to innovate and develop new solutions or adapt to changing medical landscapes and regulations could make its offerings less competitive.
• Inability to maintain and enhance its brand could impair client base expansion.
• Failure to retain and motivate key management and employees, or attract qualified personnel, could harm business and growth prospects.
• International business risks, including economic, legal, and regulatory uncertainties in Thailand, Cambodia, and Kyrgyzstan, could adversely affect operations.
• Ethical, legal, and social concerns related to assisted reproductive technology could reduce demand for services.
• Reliance on revenue from international clients makes the company vulnerable to factors like economic status of foreign clients' countries, exchange rates, natural disasters, pandemics, and geopolitical tensions.
• Fluctuations in exchange rates could materially and adversely affect results of operations and investment value.
• Governmental control of currency conversion may limit the ability to utilize net revenue effectively.
• Sales of a substantial number of securities by selling securityholders could depress the market price of Class A Ordinary Shares.
• The dual-class voting structure concentrates control with Mr. Wing Fung Alfred Siu and Ms. Hei Yue Tina Fong (66.58% voting power), limiting other shareholders' influence.
• Defects in certain leased property interests and failure to register lease agreements could lead to forced relocation and operational disruptions.
• NewGenIvf currently has no insurance coverage for its operations, exposing it to substantial costs from potential medical liabilities, disputes, and claims.
• Failure to adapt to technological developments or security breaches in computer systems could disrupt services and incur liabilities.
• Failure to comply with SEC filing deadlines could lead to enforcement actions or delisting.
• Non-compliance with highly regulated industry requirements (licensing, privacy, fraud, advertising) could result in penalties, loss of permits, and reputational damage.
• Advertising or offering gender selection services in certain jurisdictions (e.g., Hong Kong) could expose the company to significant legal and regulatory risks.
• Significant tariffs or trade restrictions could increase operational costs and disrupt supply chains.
• Litigation could be costly, time-consuming, and harm business and reputation.
• Acquisitions, strategic investments, partnerships, or alliances pose integration challenges, divert management attention, and may not yield expected benefits.

Future Outlook

NewGenIvf plans to expand its service offerings for fertility tourists across Asia Pacific, including integrated ARS and hospitality arrangements. The company intends to continue investing in upgrading its laboratories and facilities, developing advanced research capabilities, and deploying new technologies to improve ARS success rates and lower costs. Strategies also include increasing brand awareness and market share through collaborations with local hospitals and hospitality providers, social media promotions, and introducing innovative services like IVF mental health support. NewGenIvf aims to expand its service reach through strategic acquisitions and partnerships in Asia Pacific, focusing on ARS providers with conventional licenses and recognized brands, and exploring corporate benefit programs for fertility treatments.

Management Comments

• "NewGenIvf believes that its licenses and/or access to mature technologies contribute to its ability to identify and tailor ARS services to individual patients' needs."
• "NewGenIvf believes that it is therefore well-positioned to benefit from market growth driven by Asia-Pacific patients travelling to its clinics for treatment."
• "NewGenIvf believes that its existing facilities are suitable and adequate to meet its current needs."
• "NewGenIvf believes that if recovery of the PRC economy is sustainable, it might increase the demand for NewgenIvf's services and therefore in turn affect NewGenIvf's results of operations."
• "NewGenIvf is always closely monitoring the market for opportunities and has also been carrying out various fundraising projects to improve the Company's cash flow position."

Industry Context

NewGenIvf operates in the rapidly growing Asia-Pacific Assisted Reproductive Services (ARS) market, driven by factors such as rising infertility rates (e.g., Thailand 15.4%, India 13.8%, China 17.8% in 2022), increasing maternal age, and growing social acceptance of ARS. The market is projected to reach $37.4 billion by 2030. The company aims to address challenges like financial barriers and limited access to treatment in the region. Its focus on fertility tourism aligns with the demand from countries like China and India, influenced by policies like China's Three-Child policy. The industry faces competition from other regional providers, and the company differentiates itself through comprehensive service offerings, experienced staff, and proprietary technology like MicroSort. Geopolitical events and economic conditions in key markets like China can significantly impact demand.

Comparison to Industry Standards

• NewGenIvf's reported IVF implantation rate of 70.9% and miscarriage rate reduction by 26.6% due to PGS technology are presented as improvements in clinical outcomes, but no direct comparison to specific industry benchmarks or competitor success rates is provided in the document.
• The average cost per IVF cycle by NewGenIvf is stated to be around $7,000 (excluding medication), which is noted as 'relatively low cost, as compared with the US market,' but no specific U.S. market average or competitor pricing is detailed for direct comparison.
• The document states that NewGenIvf was 'one of the few ARS providers in Kyrgyzstan and one of the few companies in Kyrgyzstan that is licensed to offer surrogacy services' as of December 31, 2024, indicating a strong competitive position in that specific regional niche, but does not name specific comparable companies or their market share.
• The company highlights its 'long-standing position' and 'track record of success' in the Asia-Pacific IVF industry since 2014, but does not provide specific market share data or rankings against named competitors like other regional fertility service providers.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal or administrative proceedings as of December 31, 2024 and 2023.
• A past lawsuit brought by a specialist against NewGenIvf regarding disputed remuneration resulted in a settlement of approximately $98,000.

Related Party Transactions

• Historically, cash from operating activities was distributed to Mr. Wing Fung Alfred Siu and Ms. Hei Yue Tina Fong (shareholders and directors, husband and wife), resulting in amounts due from them. As of December 31, 2023, the largest aggregate amount due from them was $2,240,872, which has since been repaid.
• As of December 31, 2024, the aggregate balance of amount due to Mr. Siu and Ms. Fong was $92,651.
• Remuneration paid to Mr. Siu was $190,000 in 2024 and $125,000 in 2023.
• Remuneration paid to Ms. Fong was $190,000 in 2024 and $125,000 in 2023.
• Mr. Siu Wing Fung waived a balance of $88,151 due from the company in 2023.
• Harcourt Limited, controlled by Mr. Siu and Ms. Fong, is a related party with an amount due to it of $(61,802) as of December 31, 2024.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from the resale of up to 22,027,500 Class A Ordinary Shares by selling securityholders, and potential future dilution from the White Lion equity line of credit and convertible note conversions. The company's net loss and accumulated deficit directly impact shareholder equity. The dual-class voting structure limits the influence of Class A shareholders.
• **Employees**: The company plans to increase headcount, particularly for lab and nurse teams, which could lead to more employment opportunities. The amended Share Incentive Plan aims to attract and retain qualified personnel through equity awards.
• **Customers**: The company's strategic focus on expanding services, investing in facilities, and deploying advanced technologies aims to provide high-quality, cost-effective, and comprehensive fertility solutions, potentially benefiting customers with improved success rates and wider access to services. However, reorganization in Kyrgyzstan led to cessation of surrogacy services, impacting customers seeking those specific services.
• **Suppliers**: The company's procurement team focuses on selecting cost-effective and reliable suppliers, primarily pharmaceutical companies. Changes in supplier relationships or quality issues could impact operations.
• **Creditors**: The company's substantial indebtedness and going concern risk pose a risk to creditors, although management is actively pursuing financing to address liquidity shortfalls. Promissory notes and convertible bonds are significant liabilities.

Next Steps

• Continue to expand fertility services for fertility tourists across Asia Pacific, integrating offerings with hospitality services.
• Invest in upgrading existing laboratories and facilities, and develop advanced research capabilities to improve ARS success rates and lower costs.
• Actively promote technological cooperation with tertiary institutions to enhance IVF success rates.
• Increase brand awareness and market share through collaborations with local hospitals, companies, and premium hospitality providers, and social media marketing.
• Introduce innovative treatment services, such as IVF mental health services.
• Expand service reach through strategic acquisitions and/or partnerships in Asia Pacific, focusing on ARS providers with conventional licenses and recognized brands.
• Explore expanding client base by offering fertility services as part of corporate benefit programs in Asia.
• Establish a home country gynecologist partnership program to offer treatment services with reduced overseas time requirements for clients.
• Continue to monitor the market for opportunities and carry out fundraising projects to improve cash flow and address going concern issues.

Key Dates

Recommendation

Keywords

Assisted Reproductive Services, IVF, In Vitro Fertilization, Fertility Treatment, Surrogacy, Egg Donation, MicroSort Technology, Preimplantation Genetic Screening, PGS, Next-Generation Sequencing, NGS, Preimplantation Genetic Diagnosis, PGD, Egg Freezing, Asia-Pacific Fertility Market, Nasdaq Compliance, Equity Line of Credit, Convertible Notes, Healthcare, Medical Tourism, Thailand, Cambodia, Kyrgyzstan